Explore

Trendline Trendline
Understanding Menopause: Symptoms, Stages, and Treatment Options

Understanding Menopause: Symptoms, Stages, and Treatment Options

Understanding Menopause: Symptoms, Stages, and Treatment Options
Trendline Trendline
Penélope Cruz Discusses Early Perimenopause and Its Impact

Penélope Cruz Discusses Early Perimenopause and Its Impact

Penélope Cruz Discusses Early Perimenopause and Its Impact
Trendline Trendline
AIM ImmunoTech Highlights Ampligen's Potential in Biodefense

AIM ImmunoTech Highlights Ampligen's Potential in Biodefense

AIM ImmunoTech Highlights Ampligen's Potential in Biodefense
Rapid Read Rapid Read
Study Suggests Stopping Statins at 75 May Be Safe for Healthy Adults

Study Suggests Stopping Statins at 75 May Be Safe for Healthy Adults

A study published in the Lancet Healthy Longevity suggests that discontinuing statins at age 75 may not increase mortality risk for healthy adults with no history of cardiovascular disease. Conducted in France, the study involved 1,160 participants who were randomly assigned to either continue or stop taking statins. Over three years, the study found no significant difference in major cardiovascular events or mortality between the two groups. The findings highlight the need for personalized medical decisions regarding statin use in older adults, considering individual health status and risk factors.
Rapid Read Rapid Read
SLENYTO® Melatonin Tablets Approved in Canada for Pediatric Insomnia

SLENYTO® Melatonin Tablets Approved in Canada for Pediatric Insomnia

SLENYTO®, an extended-release melatonin tablet, is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and Smith-Magenis syndrome (SMS). Developed by Neurim Pharmaceuticals, SLENYTO® is designed to mimic natural melatonin secretion and has been clinically evaluated for safety and efficacy in pediatric patients. The approval by Health Canada addresses a significant unmet need for children with these conditions, who often experience disrupted sleep due to altered melatonin secretion.
Trendpost Trendpost
How Skincare During PMS Quietly Outlasts Every Beauty Trend

How Skincare During PMS Quietly Outlasts Every Beauty Trend

Forget fleeting beauty fads. The secret to consistently better skin lies in understanding your hormonal cycle and adjusting your routine for PMS.
Rapid Read Rapid Read
Semaglutide Shows Promise in Reducing Cardiovascular Events in Obese Patients

Semaglutide Shows Promise in Reducing Cardiovascular Events in Obese Patients

Semaglutide, marketed under names such as Ozempic and Wegovy, has demonstrated significant cardiovascular benefits in recent clinical trials. The SELECT trial, published in the New England Journal of Medicine, highlighted a 20% reduction in major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death, among overweight or obese patients with pre-existing heart disease but no diabetes. This development marks a transition for semaglutide from a diabetes treatment to a broader cardiometabolic platform, offering protection to the heart, blood vessels, and kidneys across diverse patient groups. The drug's efficacy in weight loss was also noted, with patients achieving a mean body weight reduction of about 9.4%.
Trendline Trendline
AbCellera Biologics' Menopause Treatment Shows Promising Phase 2 Results

AbCellera Biologics' Menopause Treatment Shows Promising Phase 2 Results

AbCellera Biologics' Menopause Treatment Shows Promising Phase 2 Results
Trendline Trendline
Managing Night Sweats: Effective Strategies for Improved Sleep

Managing Night Sweats: Effective Strategies for Improved Sleep

Managing Night Sweats: Effective Strategies for Improved Sleep
Trendline Trendline
AbCellera's ABCL-635 Shows Promising Results in Menopause Hot Flash Treatment

AbCellera's ABCL-635 Shows Promising Results in Menopause Hot Flash Treatment

AbCellera's ABCL-635 Shows Promising Results in Menopause Hot Flash Treatment
Rapid Read Rapid Read
RSV-B Resistance to Nirsevimab Detected in Infants, Highlighting Need for Genomic Surveillance

RSV-B Resistance to Nirsevimab Detected in Infants, Highlighting Need for Genomic Surveillance

A study conducted in France has identified resistance to the monoclonal antibody nirsevimab in respiratory syncytial virus B (RSV-B) among infants with breakthrough infections. The POLYRES-2 study analyzed over 1,000 RSV cases, revealing that resistance was primarily found in RSV-B, with 12.5% of breakthrough infections showing resistance-associated mutations. These mutations were not present in infants who had not received nirsevimab, suggesting they emerged under selective pressure from the prophylaxis. Despite these findings, the overall effectiveness of nirsevimab remains high, with resistance confined to a small proportion of cases.
Rapid Read Rapid Read
New Hormone Pathway Discovery Offers Hope for Treating Liver Inflammation

New Hormone Pathway Discovery Offers Hope for Treating Liver Inflammation

Researchers at McMaster University have discovered a new signaling pathway involving the hormone GDF15, which may protect the liver from inflammation independently of weight loss. This finding, published in Cell Metabolism, reveals that GDF15 activates a brain-to-liver neural pathway that increases glucocorticoid release, helping to reduce liver inflammation and fibrosis. The discovery opens new possibilities for treating metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. The research suggests that GDF15 could be part of the body's natural defense system against chronic liver injury.